KLA Corporation heads into September with a striking split: the stock has dropped 7% on the week, yet short sellers have been quietly pulling back. That divergence — price weakness without fresh short conviction — is the defining tension for the name right now.
The short-interest story is one of steady unwinding. Shorts have trimmed by 9.3% over the past week and by 13.3% over the past month, bringing SI to 18.7% of free float. That is still a meaningful level, but the direction of travel is clearly lower — from a peak above 33 million shares in late July, the position has been cut to roughly 24.6 million shares. The borrow market reinforces the picture: cost to borrow has fallen 33% on the week to just 0.3%, a multi-month low, and availability is effectively uncapped, with over 1.2 billion shares available to lend. There is no squeeze mechanics building here. Availability is at the loosest end of the 52-week range — the opposite of a compressed borrow market. Options positioning tells a similar story of stasis: the put/call ratio at 1.56 is almost perfectly in line with its 20-day average of 1.56, with a z-score of essentially zero. Nothing in the options market signals unusual hedging or directional pressure right now.
The Street, however, has grown notably more cautious since the July 28 earnings print — which saw the stock fall 16% in a single session. Most analysts moved after that result, and the direction was mostly downward on targets even where ratings were held. UBS is the most recent to act, lowering its target to $200 from $215 on September 1 while staying Neutral. JP Morgan raised its target to $238 from $200, a notable bullish outlier given the post-earnings carnage. Needham and Cantor Fitzgerald both stood firm at $270 and $325 respectively. The consensus price target of $233.77 implies roughly 37% upside from the $170.89 close — a wide gap that reflects how sharply the stock has de-rated, not renewed analyst confidence. Factor scores underscore the difficulty: EPS momentum over 90 days ranks in just the 2nd percentile of the universe, and the 12-month forward EPS growth estimate ranks 11th. The analyst recommendation differential, though, ranks 87th — meaning the buy/sell ratio relative to peers is still relatively constructive even after the wave of target cuts.
The insider activity from early August is worth noting, though it warrants context. On August 1 and August 3, five insiders filed Form F transactions — tax-withholding sales tied to equity vesting, not discretionary open-market selling. CEO Richard Wallace filed the largest, with roughly 32,000 shares withheld across the two dates at approximately $182.82. These are compensation mechanics, not conviction moves, and the 90-day net figure for open-market trades is flat at zero. Nothing in the insider register suggests executives are actively reducing exposure beyond what vesting schedules require.
The week of selling that took the stock from roughly $183 to $170 has been broad-based across the semiconductor equipment space. Peers AMAT and LRCX both fell around 8% on the week, while ONTO and ACMR dropped more than 12%. KLA's 7% decline is actually shallower than several of its closest correlated names — a reversal from the pattern of earlier in the year, when KLAC was a notable underperformer. With the next earnings event scheduled for October 30, the next major test of whether that July 28 gap down marked the worst of the bad news — or just the beginning of a recalibration lower — is still eight weeks away.
See the live data behind this article on ORTEX.
Open KLAC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
